Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole DDI with Saruparib in Advanced Solid Malignancies
NCT05573724Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of saruparib in malignant solid tumor, sponsored by AstraZeneca. Primary endpoints: Area under the concentration-time curve from time zero to infinity, AUC from time zero to time of last measurable concentration and 5 more. Started Nov 2022; status: completed.
02
Drugs
saruparib
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT05573724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05573724.